Dare Bioscience (DARE) Expected to Announce Earnings on Monday

Dare Bioscience (NASDAQ:DARE) is projected to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $0.7520 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:30 PM ET.

Dare Bioscience Stock Up 4.6%

Shares of DARE opened at $1.36 on Monday. The company’s 50-day simple moving average is $1.70 and its 200-day simple moving average is $1.91. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.18 and a current ratio of 1.18. Dare Bioscience has a 1 year low of $1.27 and a 1 year high of $9.19. The stock has a market capitalization of $19.43 million, a PE ratio of -0.73 and a beta of 0.96.

Hedge Funds Weigh In On Dare Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in DARE. Raymond James Financial Inc. increased its stake in shares of Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after buying an additional 13,650 shares during the period. LPL Financial LLC purchased a new position in Dare Bioscience in the fourth quarter worth approximately $28,000. Finally, Virtu Financial LLC purchased a new position in Dare Bioscience in the third quarter worth approximately $37,000. 6.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DARE. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Dare Bioscience in a report on Tuesday, December 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.